house dust mite allergy market 2027
DelveInsight's 'House Dust Mite Allergy - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of House Dust Mite Allergy from 2016 to 2027 segmented by the US, EU-5 countries and Japan. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2016-2027
House Dust Mite Allergy - Disease Understanding and Treatment Algorithm
The DelveInsight House Dust Mite Allergy market report gives the thorough understanding of the House Dust Mite Allergy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, treatment algorithms and treatment guidelines in the US, Europe, and Japan.
House Dust Mite Allergy Epidemiology
The House Dust Mite Allergy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented into two parts: Total Prevalent Population of Respiratory Allergy and Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in 7 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan].
According to DelveInsight, the prevalent cases of House Dust Mite Induced Respiratory Allergy was 50,703,100 in 2016 in 7MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of House Dust Mite Allergy with 69,310,852 prevalent cases in 2016.
House Dust Mite Allergy Drug Chapters
This segment of the House Dust Mite Allergy report encloses the detailed analysis of marketed drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
House Mite Allergy is a hypersensitive (IgE mediated) reaction to proteins in the excrement of dust mites. These proteins can cause an allergic reaction in the respiratory passages causing the symptoms of hay fever and asthma. It can often aggravate atopic dermatitis (eczema) in people who have this problem, causing facial eczema that can be difficult to treat. Odactra by Merck Sharp & Dohme Corp. and Actair by Shionogi & Co. are currently approved therapies for House Dust Mite Allergies.
House Dust Mite Allergy Market Outlook
The House Dust Mite Allergy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The report provides global market share of House Dust Mite Allergy i.e., 7 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)] and Japan. In 2016, global market size of House Dust Mite Allergy was USD 258 million and, is expected to grow at a CAGR of XX% during the forecast period of 2018-2027.
The region-wise market size for House Dust Mite Allergy in US, EU-5 countries (Germany, France, Italy, Spain and the U.K.) and Japan shows highest market size in US, followed by Germany, the lowest being in the Spain.
House Dust Mite Allergy Report Insights
• Patient Population
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
House Dust Mite Allergy Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Highly Analyzed Market
House Dust Mite Allergy Report Assessment
• Current Treatment Practices
• Unmet Needs
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the House Dust Mite Allergy market
• Organize sales and marketing efforts by identifying the best opportunities for House Dust Mite Allergy market
• To understand the future market competition in the House Dust Mite Allergy market.
1. Key Insights
2. House Dust Mite Allergy Market Overview at a Glance
2.1. Market Share (%) Distribution of House Dust Mite Allergy in 2017
2.2. Market Share (%) Distribution of House Dust Mite Allergy in 2027
3. House Dust Mite Allergy: Disease Background and Overview
3.1. Introduction
3.2. Classification of House Dust Mites (HDM)
3.3. HDM Anatomy and Feeding
3.4. Clinical Signs and Symptoms
3.5. Factors Influencing Exposure, Sensitization, and Allergy to HDM
3.6. Atopic Sensitization to Dust Mites
3.7. HDMs in allergic disease
3.8. Diagnosis
3.9. Management
3.10. Current Therapeutic Strategies
4. Epidemiology and Patient Population
4.1. Key Findings
5. 7MM Total Prevalence of HDM Induced Respiratory Allergy
6. Country Wise-Epidemiology of House Dust Mite Allergy
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of Respiratory Allergy in the United States
6.1.3. Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in the United States
6.2. EU5 Countries
6.2.1. Assumptions and Rationale
6.3. Germany
6.3.1. Total Prevalence of Respiratory Allergies in Germany
6.3.2. Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in Germany
6.4. France
6.4.1. Total Prevalence of Respiratory Allergies in France
6.4.2. Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in France
6.5. Italy
6.5.1. Total Prevalence of Respiratory Allergies in Italy
6.5.2. Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies Allergy in Italy
6.6. Spain
6.6.1. Total Prevalent Population of Respiratory Allergy in Spain
6.6.2. Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in Spain
6.7. United Kingdom
6.7.1. Total Prevalence of Respiratory Allergies in UK
6.7.2. Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in UK
6.8. Japan
6.8.1. Total Prevalence of Respiratory Allergies in Japan
6.8.2. Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in Japan
6.9. Treatment Algorithm
6.9.1. Desensitization therapy
6.9.2. Treatment Guidelines for House Dust Mite Allergy
6.9.3. Japanese guidelines for allergic rhinitis 2017
7. Unmet Needs
8. Marketed Drug Analysis
8.1. Odactra: Merck Sharp & Dohme Corp.
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Safety and Efficacy
8.1.6. Product Profile
8.2. Actair: Shionogi & Co.
8.2.1. Drug Description
8.2.2. Regulatory Milestones
8.2.3. Mechanism of Action
8.2.4. Advantages & Disadvantages
8.2.5. Safety and Efficacy
8.2.6. Product Profile
9. House Dust Mite Allergy: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of House Dust Mite Allergy in 7MM
9.3. Market size of House Dust Mite Allergy by Therapy-Type in 7MM
9.4. Market Size of House Dust Mite Allergy by therapies in 7MM
10. The United States Market Outlook
10.1. United States Market Size
10.2. Total Market size of House Dust Mite Allergy in the United States
10.3. Market size of House Dust Mite Allergy by Therapy-type in the United States
10.4. Market Size of House Dust Mite Allergy by Therapies in the US
11. EU-5 Countries: Market Outlook
11.1. Germany
11.1.1. Total Market size of House Dust Mite Allergy in Germany
11.1.2. Market Size of House Dust Mite Allergy by Therapy-type in Germany
11.1.3. Market Size of House Dust Mite Allergy by Therapies in Germany
11.2. France
11.2.1. Total Market size of House Dust Mite Allergy in France
11.2.2. Market Size of House Dust Mite Allergy by Therapy-type in France
11.2.3. Market Size of House Dust Mite Allergy by Therapies in France
11.3. Italy
11.3.1. Total Market size of House Dust Mite Allergy in Italy
11.3.2. Market Size of House Dust Mite Allergy by Therapy-type in Italy
11.3.3. Market Size of House Dust Mite Allergy by Therapies in Italy
11.4. Spain
11.4.1. Total Market size of House Dust Mite Allergy in Spain
11.4.2. Market Size of House Dust Mite Allergy by Therapy-type in Spain
11.4.3. Market Size of House Dust Mite Allergy by Therapies in Spain
11.5. United Kingdom
11.5.1. Total Market size of House Dust Mite Allergy in UK
11.5.2. Market Size of House Dust Mite Allergy by Therapy-type in UK
11.5.3. Market Size of House Dust Mite Allergy by Therapies in UK
11.6. Japan: Market Outlook
11.6.1. Total Market size of House Dust Mite Allergy in Japan
11.6.2. Market Size of House Dust Mite Allergy by Therapy-type in Japan
11.6.3. Market Size of House Dust Mite Allergy by Therapies in Japan
12. Market Drivers
13. Market Barriers
14. Appendix
14.1. Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
List of Tables:
Table 1: Total Prevalence of HDM Induced Respiratory Allergy in the 7MM (2016-2027)
Table 2: Total Prevalence of Respiratory Allergies in the United States (2016-2027)
Table 3: Prevalence of Allergic Rhinitis [AR] by Severity in the United States (2016-2027)
Table 4: Prevalence of Allergic Asthma [AA] by Severity in the United States (2016-2027)
Table 5: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in the United States (2016-2027)
Table 6: Total Prevalence of Respiratory Allergies in Germany (2016-2027)
Table 7: Prevalence of Allergic Rhinitis [AR] by Severity in Germany (2016-2027)
Table 8: Prevalence of Allergic Asthma [AA] in Germany (2016-2027)
Table 9: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in Germany
Table 10: Total Prevalence of Respiratory Allergies in France (2016-2027)
Table 11: Prevalence of Allergic Rhinitis [AR] by Severity in France (2016-2027)
Table 12: Prevalence of Allergic Asthma [AA] by Severity in France (2016-2027)
Table 13: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in France (2016-2027)
Table 14: Total Prevalence of Respiratory Allergies in Italy (2016-2027)
Table 15: Prevalence of Allergic Rhinitis [AR] by Severity in Italy (2016-2027)
Table 16: Prevalence of Allergic Asthma [AA] by Severity in Italy (2016-2027)
Table 17: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies Allergy in Italy (2016-2027)
Table 18: Total Prevalent Population of House Dust Mite Allergy in Spain (2016-2027)
Table 19: Prevalence of Allergic Rhinitis [AR] by Severity in Spain (2016-2027)
Table 20: Prevalence of Allergic Asthma [AA] by Severity in Spain (2016-2027)
Table 21: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in Spain (2016-2027)
Table 22: Total Prevalence of Respiratory Allergies in UK (2016-2027)
Table 23: Prevalence of Allergic Rhinitis [AR] by Severity in UK (2016-2027)
Table 24: Prevalence of Allergic Asthma [AA] by Severity in UK (2016-2027)
Table 25: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in UK (2016-2027)
Table 26: Total Prevalence of Respiratory Allergies in Japan (2016-2027)
Table 27: Prevalence of Allergic Rhinitis [AR] by Severity in Japan (2016-2027)
Table 28: Prevalence of Allergic Asthma [AA] by Severity in Japan (2016-2027)
Table 29: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in Japan (2016-2027)
Table 30: Market Size of House Dust Mite Allergy in the 7MM in USD Million (2016-2027)
Table 31: Market Size of House Dust Mite Allergy by therapy-type in the 7MM in USD Million (2016-2027)
Table 32: Market Size of House Dust Mite Allergy in the 7MM in USD Million (2016-2027)
Table 33: United States Market Size of House Dust Mite Allergy in USD Million (2016-2027)
Table 34: Market Size of House Dust Mite Allergy by therapy-type in the 7MM in USD Million (2016-2027)
Table 35: Market Size of House Dust Mite Allergy in the 7MM in USD Million (2016-2027)
Table 36: United States Market Size of House Dust Mite Allergy in USD Million (2016-2027)
Table 37: Market Size of House Dust Mite Allergy by therapy-type in the 7MM in USD Million (2016-2027)
Table 38: Market Size of House Dust Mite Allergy in the 7MM in USD Million (2016-2027)
Table 39: French Market Size of House Dust Mite Allergy in USD Million (2016-2027)
Table 40: Market Size of House Dust Mite Allergy by therapy-type in the 7MM in USD Million (2016-2027)
Table 41: Market Size of House Dust Mite Allergy in the 7MM in USD Million (2016-2027)
Table 42: Italina Market Size of House Dust Mite Allergy in USD Million (2016-2027)
Table 43: Market Size of House Dust Mite Allergy by therapy-type in the 7MM in USD Million (2016-2027)
Table 44: Market Size of House Dust Mite Allergy in the 7MM in USD Million (2016-2027)
Table 45: Spanish Market Size of House Dust Mite Allergy in USD Million (2016-2027)
Table 46: Market Size of House Dust Mite Allergy by therapy-type in the 7MM in USD Million (2016-2027)
Table 47: Market Size of House Dust Mite Allergy in the 7MM in USD Million (2016-2027)
Table 48 UK Market Size of House Dust Mite Allergy in USD Million (2016-2027)
Table 49: Market Size of House Dust Mite Allergy by therapy-type in the 7MM in USD Million (2016-2027)
Table 50: Market Size of House Dust Mite Allergy in the 7MM in USD Million (2016-2027)
Table 51: Japanese Market Size of House Dust Mite Allergy in USD Million (2016-2027)
Table 52: Market Size of House Dust Mite Allergy by therapy-type in the 7MM in USD Million (2016-2027)
Table 53: Market Size of House Dust Mite Allergy in the 7MM in USD Million (2016-2027)
List of Figures:
Figure 1: Components of HDM, and their associated fecal pellets and dust, which activate the immune system to initiate an inflammatory response
Figure 2: A photograph of a house dust mite
Figure 3: Pathways for HDM allergen interaction with the innate immune system
Figure 4: Potential enhancement of the allergic response by HDM allergens. Uptake of HDM allergen particles, immediate allergic reaction, and sustained inflammatory response.
Figure 5: Total Prevalence of HDM Induced Respiratory Allergy in the 7MM (2016-2027)
Figure 6: Total Prevalence of Respiratory Allergies in the United States (2016-2027)
Figure 7: Prevalence of Allergic Rhinitis [AR] by Severity in the United States (2016-2027)
Figure 8: Prevalence of Allergic Asthma [AA] by Severity in the United States (2016-2027)
Figure 9: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in the United States (2016-2027)
Figure 10: Total Prevalence of Respiratory Allergies in Germany (2016-2027)
Figure 11: Prevalence of Allergic Rhinitis [AR] by Severity in Germany (2016-2027)
Figure 12: Prevalence of Allergic Asthma [AA] in Germany (2016-2027)
Figure 13: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in Germany (2016-2027)
Figure 14: Total Prevalence of Respiratory Allergies in France (2016-2027)
Figure 15:Prevalence of Allergic Rhinitis [AR] by Severity in France (2016-2027)
Figure 16:Prevalence of Allergic Asthma [AA] by Severity in France (2016-2027)
Figure 17: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in France (2016-2027)
Figure 18: Total Prevalence of Respiratory Allergies in Italy (2016-2027)
Figure 19:Prevalence of Allergic Rhinitis [AR] by Severity in Italy (2016-2027)
Figure 20:Prevalence of Allergic Asthma [AA] by Severity in Italy (2016-2027)
Figure 21: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies Allergy in Italy (2016-2027)
Figure 22: Total Prevalent Population of House Dust Mite Allergy in Spain (2016-2027)
Figure 23: Prevalence of Allergic Rhinitis [AR] by Severity in Spain (2016-2027)
Figure 24: Prevalence of Allergic Asthma [AA] by Severity in Spain (2016-2027)
Figure 25: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in Spain (2016-2027)
Figure 26: Total Prevalence of Respiratory Allergies in UK (2016-2027)
Figure 27: Prevalence of Allergic Rhinitis [AR] by Severity in UK (2016-2027)
Figure 28: Prevalence of Allergic Asthma [AA] by Severity in UK (2016-2027)
Figure 29: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in UK (2016-2027)
Figure 30: Total Prevalence of Respiratory Allergies in Japan (2016-2027)
Figure 31: Prevalence of Allergic Rhinitis [AR] by Severity in Japan (2016-2027)
Figure 32: Prevalence of Allergic Asthma [AA] by Severity in Japan (2016-2027)
Figure 33: Total Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in Japan (2016-2027)
Figure 34: Treatment Algorithm for House Dust Mite Allergy (HDM)
Figure 35: Unmet Needs of House Dust Mite Allergy
Figure 36: 7 Major Market Size of House Dust Mite Allergy in USD Million (2016-2027)
Figure 37: Market Size of House Dust Mite Allergy by therapy-type in 7MM in USD Million (2016-2027)
Figure 38: Market Size of House Dust Mite Allergy by therapies in 7MM in USD Million (2016-2027)
Figure 39: Market Size of House Dust Mite Allergy in the United States, USD Millions (2016-2027)
Figure 40: Market Size of House Dust Mite Allergy by therapy-type in 7MM in USD Million (2016-2027)
Figure 41: Market Size of House Dust Mite Allergy by therapies in 7MM in USD Million (2016-2027)
Figure 42: Market Size of House Dust Mite Allergy in Germany, USD Millions (2016-2027)
Figure 43: Market Size of House Dust Mite Allergy by therapy-type in Germany in USD Million (2016-2027)
Figure 44: Market Size of House Dust Mite Allergy by therapies in Germany in USD Million (2016-2027)
Figure 45: Market Size of House Dust Mite Allergy in France, USD Millions (2016-2027)
Figure 46: Market Size of House Dust Mite Allergy by therapy-type in France in USD Million (2016-2027)
Figure 47: Market Size of House Dust Mite Allergy by therapies in France in USD Million (2016-2027)
Figure 48: Market Size of House Dust Mite Allergy in Italy, USD Millions (2016-2027)
Figure 49: Market Size of House Dust Mite Allergy by therapy-type in Italy in USD Million (2016-2027)
Figure 50: Market Size of House Dust Mite Allergy by therapies in Italy in USD Million (2016-2027)
Figure 51: Market Size of House Dust Mite Allergy in Spain, USD Millions (2016-2027)
Figure 52: Market Size of House Dust Mite Allergy by therapy-type in Spain in USD Million (2016-2027)
Figure 53: Market Size of House Dust Mite Allergy by therapies in Spain in USD Million (2016-2027)
Figure 54: Market Size of House Dust Mite Allergy in UK, USD Millions (2016-2027)
Figure 55: Market Size of House Dust Mite Allergy by therapy-type in the UK in USD Million (2016-2027)
Figure 56: Market Size of House Dust Mite Allergy by therapies in the UK in USD Million (2016-2027)
Figure 57: Market Size of House Dust Mite Allergy in Japan, USD Millions (2016-2027)
Figure 58: Market Size of House Dust Mite Allergy by therapy-type in Japan in USD Million (2016-2027)
Figure 59: Market Size of House Dust Mite Allergy by therapies in Japan in USD Million (2016-2027)
Figure 60: Market Drivers
Figure 61:Market Barriers
